CHFS vs. ELMD, QTI, NRXS, VRAYQ, VIVE, GLSI, TLSI, SLS, LXEO, and PBYI
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Electromed (ELMD), QT Imaging (QTI), NeurAxis (NRXS), ViewRay (VRAYQ), Viveve Medical (VIVE), Greenwich LifeSciences (GLSI), TriSalus Life Sciences (TLSI), SELLAS Life Sciences Group (SLS), Lexeo Therapeutics (LXEO), and Puma Biotechnology (PBYI). These companies are all part of the "medical" sector.
Nuwellis vs. Its Competitors
Electromed (NYSE:ELMD) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.
40.8% of Electromed shares are held by institutional investors. Comparatively, 65.1% of Nuwellis shares are held by institutional investors. 14.0% of Electromed shares are held by company insiders. Comparatively, 0.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Electromed has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Electromed presently has a consensus target price of $33.50, suggesting a potential upside of 79.72%. Given Electromed's stronger consensus rating and higher probable upside, research analysts clearly believe Electromed is more favorable than Nuwellis.
Electromed has a net margin of 11.34% compared to Nuwellis' net margin of -254.26%. Electromed's return on equity of 15.71% beat Nuwellis' return on equity.
Electromed has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.73 beat Nuwellis' score of 0.00 indicating that Electromed is being referred to more favorably in the media.
Summary
Electromed beats Nuwellis on 12 of the 15 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHFS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:CHFS) was last updated on 8/11/2025 by MarketBeat.com Staff
MarketBeat All Access Sale